T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood.
Vera Dunlock et al. (Dept. Tumor Immunology, research team of Annemiek van Spriel) discovered that CD45 is tightly controlled by tetraspanin protein CD53 at the cell surface of T cells. Using a combination of genetic experiments, advanced microscopy, and in vivo models, they demonstrate that CD53 is a key regulator of CD45 activity required for T cell immunity. T cells lacking CD53 were defective in cell division, interferon production and tumor rejection. These findings reveal a novel mechanism for the regulation of T cell signaling that provides valuable insight into T cell biology and immunological memory formation. This has import consequences for understanding immunity to cancer and infectious diseases.
Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. Cell Rep. 2022 Jun 28;39(13):111006. doi: 10.1016/j.celrep.2022.111006. PMID: 35767951
Vera-Marie E. Dunlock, Abbey B. Arp, Simar Pal Singh, Stéphanie Charrin, Viet Nguyen, Erik Jansen, Fleur Schaper, Martin Ter Beest, Malou Zuidscherwoude, Sjoerd J. van Deventer, Britt Nakken, Peter Szodoray, Maria C. Demaria, Mark D. Wright, Laia Querol Cano, Eric Rubinstein, Annemiek B. van Spriel.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read more
Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read more
European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant26 April 2022
The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.read more